SHAREHOLDER ALERT: AST SpaceMobile Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
19 avr. 2024 07h50 HE
|
Block & Leviton LLP
BOSTON, April 19, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against AST SpaceMobile, Inc. (NASDAQ: ASTS) for securities law violations. Investors who purchased shares and have...
SPACEMOBILE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against AST SpaceMobile, Inc. and Encourages Investors to Contact the Firm
18 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against AST...
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
07 juin 2023 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 07, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), a clinical-stage drug discovery company developing pharmacologically active drugs for use...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
24 avr. 2023 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
13 oct. 2022 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and...
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
17 août 2021 09h25 HE
|
Lixte Biotechnology Holdings, Inc.
A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
Applied Impact Robotics, Developers of an Automated Inspection Solution for Capital Intensive Infrastructure, Appoints Jim Nyquist to its Board of Directors as an Independent Director
28 juil. 2021 08h00 HE
|
Applied Impact Robotics
Sterling, Virginia, July 28, 2021 (GLOBE NEWSWIRE) -- Applied Impact Robotics (AIR), developers of a solution for the in-service inspection and maintenance of Aboveground Storage Tanks (ASTs),...
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
04 mai 2021 16h30 HE
|
Lixte Biotechnology Holdings, Inc.
Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE...
Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
28 avr. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc....